Medicine Price Transparency Under Scrutiny At Next World Health Assembly
Executive Summary
At the forthcoming 72nd World Health Assembly, delegates will discuss a resolution calling for greater transparency on medicine prices.
You may also be interested in...
Pricing And R&D Transparency Proposals Face Pushback At WHA
A draft resolution on the transparency of medicine prices and R&D costs is being discussed this week by World Health Organization members, but the pharmaceutical industry says some measures will be damaging for medicines access.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.